RxDoctor Payments Data

Anil Shivaram, MD

Ophthalmology · Claremont, CANPI 1346426293

Payments from drug & device makers

$17,999in general payments, 2019–2025

Across 137 payments — averaging $131.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$12K
  • Bausch & Lomb Americas Inc.$2K
  • Glaukos Corporation$1K
  • Sun Pharmaceutical Industries Inc.$787
  • Alcon$580
  • Smith+Nephew$433
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$8,16045%
  • Speaking & faculty fees$5,08428%
  • Travel & lodging$1,2427%
  • Food & beverage$3,49619%
  • Entertainment$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,999 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$788,658
Medicare patients
1,139
Services billed
6,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine40$31,935
XiidraLifitegrast33$24,202
LumiganBimatoprost44$18,706
BesivanceBesifloxacin Hcl79$17,135
Cyclosporine37$13,702
Prednisolone Acetate332$10,463
Difluprednate100$9,954
MieboPerfluorohexyloctane/Pf12$9,133
CombiganBrimonidine Tartrate/Timolol15$7,839
RocklatanNetarsudil Mesylat/Latanoprost15$7,562
LotemaxLoteprednol Etabonate15$7,453
Fluorometholone86$6,409
BromsiteBromfenac Sodium19$5,448
Travoprost27$4,982
Latanoprost420$4,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$140$58,48199 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$1,960$33,33545 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax, Loteprednol Etabonate$11,594$26,306111 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$53$11,05726 claims
Sun Pharmaceutical Industries Inc.Bromsite$787$5,44819 claims
AlconSimbrinza$580$4,41722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Claremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →